anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Schizophrenia is recognized as one of the most severe psychiatric disorders, with its pathogenesis likely involving genetic, epigenetic, developmental, and environmental factors. Members of the Methyl-CpG Binding Domain (MBD) Family play a crucial role in the regulation of genomic DNA methylation, and studies have implicated the association between MBD family and neurodevelopmental disorders. Copy number variations (CNVs) are a significant genetic basis for human genomic variation, also playing a critical role in the genetic processes of schizophrenia. Therefore, we aimed to evaluate the susceptibility of MBD family CNVs to schizophrenia by exploring and validating them in two separate populations using CNVplex™ and qPCR methods, and to explore the relationship between MBD family CNVs and clinical phenotypes in the overall population using chi-square tests and Fisher's exact tests. Results suggest that an increase in MBD1 gene copy number and a deficiency in MBD2 gene copy number may be associated with the risk of schizophrenia. The deficiency in MBD2 gene copy number may increase the risk of delusion of reference and delusion of persecutory in the overall sample, as well as in males. This research provides preliminary evidence supporting the association between MBD family CNVs and schizophrenia, highlighting the potential role of the MBD family in the pathogenesis of schizophrenia.
Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
In the original BIG PICTURE trial, the analysis of over 6000 subject's CCTA images found significant differences amongst patients of Arabic and south-east Asian descent, with regard to plaque burden, severity and composition. Due to the "all-comers" nature of that trial, the factors of diabetes, previous CVD, and other coronary risk factors were likely confounders in the results. In this trial, those subject selection is screened to eliminate those factors with the goal of working with a more homogenous population to perform the plaque analysis. This study is a multicenter, prospective, post marketing, observational registry study designed to describe frequency and patterns of various risk factors, indications and findings in patients who undergo CCTA.

BIG PICTURE 2 (abbreviated as "BP2") will collect data on patients from a wide variety of imaging sites (inpatient, outpatient, in-clinic CT machine). While the majority of the sites are within the US, the data collection will not be limited to US-only sites. A sub study of BP2 will perform a remote short follow-up questionnaire of subjects who were in the original Big PICTURE study.
PURPOSE: A composition containing zinc oxide and acids is provided to prevent and treat diaper rash and atopic dermatitis. CONSTITUTION: A composition for preventing and/or treating enzymatic dermatitis contains 1-14% of zinc oxide, 0.001-10% of acids, and a carrier. The acids include an acetic acid, an ascorbic acid, a citric acid, a carbonic acid, a glucuronic acid, a glyconic acid, a lactic acid, or and a malic acid. The carrier includes a lotion, a cream, gel, a stick, a spray, an ointment, a cleansing liquid wash, a solid bar, a paste, a powder, a mousse, a patch, a wound healing dressing, hydrogel, a film, or a diaper. The composition additionally contains ketoconazole, miconazole, elubiol, allantoin, calamine, dimethicone, kaolin, Vaseline, white Vaseline, cod liver oil, lanolin, or an agent of topical starch. [Reference numerals] (AA) Trypsin inhibition activity(%); (BB) Salt concentration(mM)
The prosthetic suspension plays a pivotal role in an amputee's comfort. It can also significantly impact an amputee's limb health. If the prosthesis is not held securely to the amputee's limb, relative movement between the limb and prosthetic interface can cause bruising, skin irritation and skin breakdown. These poor outcomes are uncomfortable and can lead to much more serious health conditions. A positive solution to creating secure and comfortable suspension is the use of a vacuum suspension socket. The vacuum pressure assists in preventing movement in the socket. The clinical benefits associated with vacuum suspension include volume retention, increased proprioception, secure suspension, and frequently reported observations of wound healing. However, the long term effects of vacuum suspension on circulation remain undetermined or undocumented.

This study examines a vacuum suspension system on the health of the residual limb (amputated limb). A vacuum socket creates a vacuum between the rigid prosthetic socket and prosthetic liner which is sealed to the socket. Therefore, vacuum is not directly applied to the skin of the residual limb.
PROBLEM TO BE SOLVED: To obtain a large quantity of an antibody component from goat antiserum without losing antibody activity by using glycine buffer solution in a specific pH range for buffer solution. SOLUTION: Goat antiserum is salted out by using buffer solution and salt, and an antibody-containing component is separated therefrom. Glycine buffer solution of pH8-11 is used as the buffer solution, ion intensity is preferably normally 10-500mM, and a quantity of about 0.5-2 times the antiserum is preferred. In addition, ammonium sulfate is used as the salt, the concentration of ammonium sulfate in the whole liquid is 1mol/l, in and precipitation formed in the state is removed by centrifugation. Next, ammonium sulfate is added to the obtained supernatant, and the antibody-containing component is deposited so that the concentration of ammonium sulfate may be 1.4mol/l in the whole liquid. After the deposition, dialysis is performed and the salt is removed after the centrifuged antibody-containing component is dissolved in the same buffer solution.  Thereby obtaining a large quantity of the antibody component from the goat antiserum without losing any antibody activity.
Acute diarrhoea is a common presentation in dogs, and a common reason for antimicrobial prescription and nutraceutical use. This evidence-based guideline provides recommendations for antimicrobial and probiotic treatment of canine acute diarrhoea (CAD). A multidisciplinary panel developed the recommendations by adhering to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. The opinions of stakeholders (general veterinary practitioners and dog owners) were collected and incorporated to ensure the applicability of this guideline. Four strong recommendations informed by high certainty evidence, and three conditional recommendations informed by very low or low certainty evidence, were drafted by the panel, along with an ungraded section on diagnostic work-up of dogs with acute diarrhoea. The ENOVAT guidelines initiative encourages national or regional guideline makers to use the evidence presented in this document, and the supporting systematic review, to draft national or local guidance documents.
Ictal asystole (IA) is a rare but potentially life-threatening complication of focal epilepsy. The sudden onset of loss of consciousness and drop attacks in a patient with chronic epilepsy should suggest the possibility of this complication. Once the diagnosis is established, rapid management should be considered, especially in high-risk cases. The approach does not differ between temporal and extratemporal lobe epilepsies. Strategies can be aimed at preventing the emergence of cortical epileptic activity from the beginning (surgery, antiseizure therapy), neutralizing negative chronotropic effects on the heart (cardiac neuromodulation), or restarting the heart rhythm with a pacemaker. Pacemaker implantation is not a completely complication-free treatment, and living with a device that requires care and follow-up throughout life makes alternative treatment methods more valid for young patients with many years to live or cases that could benefit from surgery. In this article, we present a patient with a left occipital glioneuronal tumor and drug-resistant occipital lobe epilepsy. IA was documented by long-term video EEG monitoring (VEM). During about 2 years of follow-up after a cardiac neuromodulation procedure, there were no drop attacks or asystole with seizures, confirmed by long-term VEM.
The present invention belongs to the field of medicine. The present invention particularly relates to an oral loratadine disintegrating tablet for treating anaphylactic diseases and a preparation method thereof. The oral loratadine disintegrating tablet comprises loratadine which is medical active ingredients and a mixture of excipient. The oral loratadine disintegrating tablet is characterized in that the excipient comprises a disintegrating agent, a filling agent, soluble polyol and a penetrating agent; the tablet comprises the following ingredients according to the proportion by weight: 20% to 50% of loratadine, 5% to 15% of disintegrating agent, 10% to 30% of soluble polyol and 1% to 5% of penetrating agent. Compared with an ordinary oral preparation, because the mucosa of gstrointestinal tracts is widely covered by medicine which is quickly disintegrated, the effect of the present invention is rapid. The medicine is absorbed by the oral mucosa, the first pass effect is cancelled, the biological availability is enhanced, and the stimulation for gstrointestinal tracts is reduced. The oral disintegrating tablet can be taken from the mouth without water, which provides convenience for people to take the medicine in an oral taking mode when water is inconveniently drunk.
Insulin resistance has been found to be the key pathophysiological factor of the metabolic syndrome and may precede the onset of impaired glucose tolerance, diabetes and dyslipidemia. Recently, nonalcoholic fatty liver disease (NAFLD), has been identified as another feature of this syndrome. Importantly, a close relation between liver fat content and hepatic insulin sensitivity has been described. We hypothesize that activation of FXR with chenodeoxycholic acid decreases hepatic de novo lipogenesis and subsequently hepatic fat content and triglyceride production. The decrease in liver fat content will be associated with improved hepatic insulin sensitivity and a decrease in hepatic glucose production.

Patients diagnosed with metabolic syndrome, familial hypertriglyceridemia or familial combined hyperlipidemia will be recruited from the the outpatients department of the Division of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel. Eligible patients will be admitted to the CRC for metabolic studies, including baseline blood samples for the measurement of hormones, cytokines and adipokines, euglycemic-hyperinsulinemic clamp studies for the assessment of glucose turnover and insulin sensitivity and in vivo NMR studies to determine intrahepatic and intramyocellular lipid content. Patients will alternatively receive chenodeoxycholic acid and placebo. The study population will be compared to a group of age, gender and weight matched normolipidemic controls.
PURPOSE:To allow drug to gradually seep from a press.-sensitive adhesive layer and to be absorbed by the diseased part at a pref. speed, by providing a base material with a press.-sensitive adhesive layer consisting of a (meth)acrylic ester, and contg. a surfactant and a drug having a metal salt. CONSTITUTION:A base material is provided with a press.-sensitive adhesive layer consisting of a polymer composed of an acrylic ester and/or a methacrylic ester. A surfactant and a drug having a metal salt of a weak or strong acid are incorporated in the adhesive layer. An anionic surfactant or an anionic/ nonionic surfactant is pref. as the surfactant to be used. The press.-sensitive adhesive consists of a polymer composed of an acrylic ester and/or a methacrylic ester because it is possible to give no strong irritation to the skin and to prevent reduction of the medicinal effect due to interaction with the drug because they have no chemical activity.
The invention discloses a Chinese traditional medicament composition which is orally taken to cure chronic pharyngitis, belonging to the Chinese traditional medicament field, wherein the invention solves the disadvantage that the present medicament is unable to radically cure. In the Chinese traditional medicament composition which is orally taken to cure chronic pharyngitis, the efficacy composition of the invention is that the proportion by weight of the materials is lily 12g, radix rehmanniae 10g, prepared rehmannia 10g, mulberry bark 8g, figwort 10g, liriope 10g, persimmon frost 6g, liquorice 3g, and reed rhizome 20g. The materials are decocted in water and taken one dose twice each day. Every 30 days is one period of treatment. After the above materials are mixed, the drug-effect synergism of the invention obtains unexpected obvious effect in the curing process of chronic pharyngitis. Through the clinical trial, the patient can take the medicament for one dose each day according to the period of treatment, the effective rate is 100%, and the curative rate is 96%.
​There are no adequate and well-controlled studies of foscarnet sodium in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Animal Data:Foscarnet did not adversely affect fertility and general reproductive performance in rats. The results of peri- and post-natal studies in rats were also negative. However, these studies used exposures that are inadequate to define the potential for impairment of fertility at human drug exposure levels. 

Daily subcutaneous doses up to 75 mg/kg administered to female rats prior to and during mating, during gestation, and 21 days post-partum caused a slight increase (< 5%) in the number of skeletal anomalies compared with the control group. Daily subcutaneous doses up to 75 mg/kg administered to rabbits and 150 mg/kg administered to rats during gestation caused an increase in the frequency of skeletal anomalies/variations. On the basis of estimated drug exposure (as measured by AUC), the 150 mg/kg dose in rats and 75 mg/kg dose in rabbits were approximately one-eighth (rat) and one-third (rabbit) the estimated maximal daily human exposure. These studies are inadequate to define the potential teratogenicity at levels to which women will be exposed.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmaceutical industry, particularly to using an eucalyptus extract for making a drug preparation or a food additive for treating and/or preventing diseases and pathologies due to disturbed dopamine and/or serotonin and/or noradrenalin reuptake. The use of the eucalyptus extract for producing the drug preparation or the food additive for treating and/or preventing neurological, psychiatric pathologies and diseases and related disorders due to disturbed dopamine and/or serotonin and/or noradrenalin reuptake, wherein the eucalyptus extract contains at least one compound of formula (I) or any of its diastereoisomeric forms: wherein R1 together with carbon atoms whereto attached forms the group C=CH2, the group or and R2 means isobutyl, -isobutyl or -isobutyl group. The use of at least one compound of formula (I). The eucalyptus extract for producing the drug preparation or the food additive. The method for producing the extract. ^ EFFECT: eucalyptus extract containing the compound of formula (I) or the compound of formula (I) are effective for producing the drug preparation or the food additive for treating and/or preventing neurological, psychiatric pathologies and diseases and related disorders due to disturbed dopamine and/or serotonin and/or noradrenalin reuptake. ^ 25 cl, 3 tbl, 7 ex
Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded. In addition perception of hypoglycemia and counter action will be assessed.
There are three doses at the dose escalation stage: Dose level I: paclitaxel (PTX) 25 mg or 0.5 mg/ml; Dose Level II: PTX 50 mg or 1.0 mg/ml; Dose Level III: PTX 75 mg or 1.5 mg/ml. At the expansion cohort, up to 12 patients will be recruited and treated with PPM at the PTX dose of 50 mg or 1.0 mg/ml to determine the efficacy.
A healthy diet has been defined in various ways. The investigators wish to compare the effects of two diets on ER positive breast cancer tissues. The diets will be administered between the time of diagnosis and the time of surgical removal. Both diets have been proposed as healthy, but differ in their composition. One constitutes a low fat diet with extra fiber, fruits and vegetable servings, while the other comprises a diet low in carbohydrate content, aiming to lower insulin secretion. Patients will be randomized to each group, with 20 assigned to the low fat arm and 45 to the low carbohydrate arm.
Novel compositions are disclosed for use in the treatment or diagnosis of bovine pasteurellosis, commonly referred to as Shipping Fever. Cell-free Pasteurella haemolytica supernatants are employed to provide individual antigen compositions, identified through reaction with sera from naturally-infected or convalescent cattle. In particular, at least seven individual P. hameolytica antigen groups were recognized in cell-free culture supernatants. Purified P. haemolytica supernatant, formulated in a suitable pharmaceutical vaccine composition is shown to elicit a specific immune response, in both cows and rabbits, directed against the individual immunoreactive P. haemolytica polypeptides identified. Also disclosed are novel recombinant cells, plasmids and bacteriophage which include transcriptionally active P. haemolytica antigen genes. Recombinant clones are similarly selected to be reactive with naturally-infected antisera. Examples, and further disclosure, are also provided which demonstrate the utility of a presently disclosed antibody and antigen compositions in immunodetection of both antigens and antibodies in various biological samples.
PURPOSE: A skin pack composition in which a powder part is dispersed over a non-aqueous dispersion solvent is provided to be softly applied on the skin and to ensure excellent viscosity after application thereof. CONSTITUTION: A skin pack composition has a powder part which is dispersed over a non-aqueous dispersion solvent. The powder part includes kaolin, terra alba, loess, gypsum, inorganic powder of mud, carbonate, and organic acid. The non-aqueous dispersion solvent is polyvalent alcohol, oil, or a mixture thereof. The non-aqueous dispersion solvent further includes a non-aqueous surfactant. The carbonate is sodium carbonate, bicarbonate, sodium sesquicarbonate, calcium carbonate, potassium carbonate, magnesium carbonate, or calcium hydrogen carbonate. The organic acid is citric acid, tartaric acid, fumaric acid, succinic acid, adipic acid, malic acid, maleic acid, or acetic acid. The powder part further contains titanium dioxide powder.
Provided is a berberine-containing dentrifice composition. The berberine therein is highly stable, and the dentrifice composition is non-irritating and has improved astringency and no unpleasant tastes. When used, said dentrifice composition feels pleasant, foams well, and has excellent foam retention characteristics. The provided dentrifice composition contains: (a) berberine; (b) sodium chloride; (c) at least one plant extract selected from among rosemary extract, sage extract,  Scutellaria baicalensis  extract, carrot extract,  Paeonia lactiflora  extract,  Lonicera japonica  extract, and  Betula platyphylla  var.  japonica  extract; (d) and a non-ionic surfactant. The mass ratio of component (b) to component (d) is between 1.5 and 20. The dentrifice composition also contains (e) lauryl sulfate, and the mass ratio of component (d) to component (e) is between 0.25 and 2.5.
PCT No. PCT/EP91/01687 Sec. 371 Date May 7, 1992 Sec. 102(e) Date May 7, 1992 PCT Filed Sep. 5, 1991 PCT Pub. No. WO92/04036 PCT Pub. Date Mar. 19, 1992.Dry extract from kava-kava drug having a total content of kava lactones of at least 50% by weight and a flavokawin content of at the most 0.3% by weight. The extract is distinguished by good water solubility and high bioavailability after oral administration. To increase the kava lactone content in the extract and decrease the flavokawin content, a process is proposed in which the raw extract is brought into solution and the content of flavokawins diminished by cold precipitation or by solvent distribution, whereafter the solution is concentrated to dryness. Drugs are made using the dry extract.
Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive axicabtagene ciloleucel IV over 30 minutes or less on day 0 and anakinra SC on days 0-6 in the absence of disease progression or unacceptable toxicity.
Next-generation risk assessment (NGRA) has emerged as a promising alternative to non-animal studies owing to the increasing demand for the risk assessment of inhaled toxicants. In this study, NGRA was used to assess the inhalation risks of two biocides commonly used as humidifier disinfectants: polyhexamethylene guanidine phosphate (PHMG-p) and chloromethylisothiazolinone/methylisothiazolinone (CMIT/MIT). Human bronchial epithelial cell transcriptomic data were processed based on adverse outcome pathways and used to establish transcriptome-based points of departure (tPODs) for each biocide. tPOD values were 0.00500-0.0510 μg/cm2 and 0.0342-0.0544 μg/cm2 for PHMG-p and CMIT/MIT, respectively. tPODs may provide predictive power comparable to that of traditional animal-based PODs (aPODs). The tPOD-based NGRA determined that both PHMG-p and CMIT/MIT present a high inhalation risk. Moreover, the identified PHMG-p posed a higher risk than CMIT/MIT, and children were identified as more susceptible population compared to adults. This finding is consistent with observations from actual exposure events. Our findings suggest that NGRA with transcriptomics offers a reliable approach for risk assessment of specific humidifier disinfectant biocides, while acknowledging the limitations of current models and in vitro systems, particularly regarding uncertainties in pharmacokinetics (PK) and pharmacodynamics (PD).